[A22-119] Pembrolizumab (breast cancer) - Addendum to Commission A22-63
Last updated 15.12.2022
Commission awarded on 08.11.2022 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.